2025 WOCIP Clusters: Navigating the New Landscape of Value (Philadelphia)

March 3, 2025

Navigating the New Landscape of Value: ICER, Diversity, and Pricing in Biopharma

This interactive meeting provides a deep dive into the evolving relationship between clinical trial diversity, health equity, and drug pricing. Attendees will gain an understanding of how ICER’s new diversity ratings will influence value assessments and inform pricing decisions. Join Clusters to discuss the value proposition for inclusive clinical trials and gain perspective to champion this evolution.​​

Discover how to champion pharmacoequity and advance health equity in your role. This dynamic one-day workshop offers interactive sessions, real-world case studies, and tools to help you embed diversity into drug development, create compelling value propositions, and drive meaningful organizational change. NOTE: Cluster attendees need a laptop, iPad, or smartphone to participate in research activities during the workshop.

KEY PROGRAM COMPONENTS:

Elevate your role in advancing health equity! This full-day workshop offers:

• Value Proposition Workshop: Interactive session focused on developing compelling value propositions for health equity initiatives, drawing on case studies and real-world examples.
• Change Management Skills Building: Practical training on change management techniques to effectively implement inclusive drug development programs within organizations.
• Data-Driven Strategies: Exploration of publicly available information (press releases, investor presentations, SEC filings) to understand market expectations and shape value propositions.
• ICER Update: Understand ICER’s approach to rating clinical trial diversity and its implications for drug development and market access.
• Networking & Collaboration: Opportunities for robust networking with peers across the industry to share best practices and foster collaboration.

EXPECTED OUTCOMES:

By the end of this meeting, attendees will:

• Develop the skills to create compelling value propositions for health equity initiatives.
• Learn practical strategies to drive organizational change and embed diversity into drug development.
• Gain a clear understanding of ICER’s clinical trial diversity rating system and its impact on drug pricing.
• Build valuable connections with peers across the biopharma industry.

CLUSTER AGENDA:

Morning

9:00- 9:15A:	Welcome/Intro to WOCIP	Co-Chairs Shelina Ramnarine/Lucy Abreu
9:15 – 9:30A:	Ice Breaker	Delvin Burton
9:30-10:00A:	Pharmacoequity by Design: The Case for Inclusive Drug Development	Charlotte Jones Burton, MD, MS
10:00-10:45A:	Equity in Numbers: The Role of ICER’s Clinical Trial Diversity Rating (CDR) Tool for the Future of Reimbursement Decision-Making [	Ebony Dashiell-Aje, PhD
10:45-11:00A:	Break
11:00 –11:30A:	Beyond the “Why”: Crafting Compelling Value Propositions for Pharmacoequity –	Pamela Simpkins
11:30A –12:00P	Know Your Market: Aligning Clinical Trials with Real-World Patient Populations to Avoid Costly Market Failures –	Angelique Hopkins, PhD
12:00-1:00P:	Lunch & Networking

Afternoon 

1:00-3:30P:	Pharmacoequity in Practice: A Workshop on Inclusive Drug Development:
3:30-4:00P:	Break
3:30-4:00P:	Create an Action Plan
4:00-4:15P:	Closing
4:15-5:00P:	Reception

Don’t miss this opportunity to build skills, gain insights, and make a difference in your role!